Last reviewed · How we verify
Surgery with Naproxen and Esomeprazole
Surgery with Naproxen and Esomeprazole is a NSAID + Proton pump inhibitor combination Small molecule drug developed by Giovana Maria Weckwerth. It is currently FDA-approved for Post-surgical pain and inflammation with gastroprotection. Also known as: Lower third molar surgery with Naproxen and Esomeprazole.
Naproxen reduces post-surgical pain and inflammation via COX inhibition, while esomeprazole protects the gastrointestinal tract by suppressing gastric acid production.
Naproxen reduces post-surgical pain and inflammation via COX inhibition, while esomeprazole protects the gastrointestinal tract by suppressing gastric acid production. Used for Post-surgical pain and inflammation with gastroprotection.
At a glance
| Generic name | Surgery with Naproxen and Esomeprazole |
|---|---|
| Also known as | Lower third molar surgery with Naproxen and Esomeprazole |
| Sponsor | Giovana Maria Weckwerth |
| Drug class | NSAID + Proton pump inhibitor combination |
| Target | COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing pain and inflammation following surgical procedures. Esomeprazole is a proton pump inhibitor that blocks H+/K+-ATPase in gastric parietal cells, reducing gastric acid secretion to mitigate NSAID-induced gastrointestinal injury and ulceration risk.
Approved indications
- Post-surgical pain and inflammation with gastroprotection
Common side effects
- Dyspepsia
- Nausea
- Headache
- Dizziness
- Gastrointestinal bleeding (reduced with PPI co-therapy)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surgery with Naproxen and Esomeprazole CI brief — competitive landscape report
- Surgery with Naproxen and Esomeprazole updates RSS · CI watch RSS
- Giovana Maria Weckwerth portfolio CI
Frequently asked questions about Surgery with Naproxen and Esomeprazole
What is Surgery with Naproxen and Esomeprazole?
How does Surgery with Naproxen and Esomeprazole work?
What is Surgery with Naproxen and Esomeprazole used for?
Who makes Surgery with Naproxen and Esomeprazole?
Is Surgery with Naproxen and Esomeprazole also known as anything else?
What drug class is Surgery with Naproxen and Esomeprazole in?
What development phase is Surgery with Naproxen and Esomeprazole in?
What are the side effects of Surgery with Naproxen and Esomeprazole?
What does Surgery with Naproxen and Esomeprazole target?
Related
- Drug class: All NSAID + Proton pump inhibitor combination drugs
- Target: All drugs targeting COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
- Manufacturer: Giovana Maria Weckwerth — full pipeline
- Therapeutic area: All drugs in Pain management / Gastroenterology
- Indication: Drugs for Post-surgical pain and inflammation with gastroprotection
- Also known as: Lower third molar surgery with Naproxen and Esomeprazole